GlassScriptPhysician profile
Ayaz T Madraswalla
NPI 1902899859
$13,885.69
in general payments reported to CMS, 2019-2025
41 companies · $695 in 2025
The $695 reported for 2025 was more than what 86% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
See the full distribution for Addiction Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,057 · 2020: $2,813 · 2021: $965 · 2022: $617 · 2023: $415 · 2024: $323 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,433.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $10,247.60 | 2019-2025 | Sublocade |
| Abbvie INC. | $375.95 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.22 | 2020-2022 | |
| Novo Nordisk INC | $328.42 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $285.87 | 2019-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $267.91 | 2019-2023 | Bevespi Aerosphere, Breztri |
| Merck Sharp & Dohme LLC | $187.70 | 2019-2025 | Capvaxive, Gardasil 9, Enflonsia |
| Glaxosmithkline, LLC. | $170.62 | 2019-2023 | Shingrix, Arexvy |
| Eisai INC. | $164.99 | 2020-2025 | |
| Gilead Sciences, INC. | $145.26 | 2025 | Epclusa |
| Pfizer INC. | $123.86 | 2019-2023 | |
| Amgen INC. | $108.78 | 2019-2025 | Evenity, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.56 | 2019-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $91.20 | 2022-2025 | Rexulti |
| Exact Sciences Corporation | $86.32 | 2023-2025 | Cologuard Collection Kit |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayaz Madraswalla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.